Objectives: The aim of our study was to assess immunological changes in hospital employees vaccinated five years ago with a recombinant hepatitis B vaccine.
Materials And Methods: 148 hospital employees were examined at different time periods during 5 years following a three-dose schedule of intramuscular immunization with a recombinant DNA hepatitis B vaccine (Engerix-B).
Results: At the end of a 5-year period, 20 vaccinees (13.5%) demonstrated a low level of HBs antibodies, namely < 10 mIU/ml being evaluated as lack of protection, 46 (31.1%) showed titers between 11 and 100 mIU/ ml corresponding to feeble protection, 54 (36.5%) were with titers > 100 mIU/ml considered as sufficiently protected and, surprisingly, in 28 vaccinated persons (18.9%), titers of HBs Ab were over 1000 mIU/ml corresponding to high protection. The HBsAg were never detected among the entire vaccinated group. Averaged amounts of serum immunoglobulins (IgG, IgM, IgA) were lower relatively to normal values only among unprotected or feebly protected vaccinees.
Conclusions: Our data demonstrate that postvaccinal titers are in linear dependence on the time elapsed since the vaccination and also evidence that some other immunological factors influence the outcome of vaccination.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Decreasing hepatitis B seroprevalence in pregnant women in Taiwan between 2016 and 2021: a claim-based cohort study.
BMC Public Health
January 2025
Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.
Background: Hepatitis B virus (HBV) surface antigen (HBsAg) seroprevalence was high before the national vaccine policy was introduced in Taiwan, indicating significant HBV infection rates. The success of the HBV immunization program and other preventive measures likely led to decreased HBsAg prevalence among pregnant women. This study reports on the HBV seroprevalence among pregnant women in Taiwan from 2016 to 2021, including those potentially affected by the universal hepatitis B vaccination at birth.
View Article and Find Full Text PDFLong-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
Vaccine
January 2025
Zhengding County Center for Disease Control and Prevention, Shijiazhuang 050800, China. Electronic address:
To evaluate the long-term efficacy and anamnestic response of Chinese hamster ovary (CHO) cell-derived hepatitis B vaccine (CHO-HepB) after 18-20 years, a cross-sectional survey was conducted in seven communities in Zhengding County at the end of 2017. The birth cohort 1997-1999 vaccinated primarily with three doses of CHO-HepB were enrolled in the survey. The HBV serological markers were quantified using the Chemiluminescence method.
View Article and Find Full Text PDFProtection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
Vaccine
January 2025
Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Seoul National University Medical Research Center (SNUMRC), Seoul 03080, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Electronic address:
Tuberculosis (TB) remains a significant global health issue due to the limited efficacy of the Bacillus Calmette-Guérin (BCG) vaccine, highlighting the need for the development of an improved TB vaccine. In this study, we created a novel TB subunit vaccine consisting of TB-secreted chorismate mutase (TBCM) (Rv1885c) and a hepatitis B virus (HBV)-derived peptide (Poly6), which elicits Type I interferon responses, both with and without an alum adjuvant. We evaluated the immunogenicity, protective efficacy, and therapeutic efficacy of this vaccine candidate in an in vivo mouse model.
View Article and Find Full Text PDFPrediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.
PLoS Comput Biol
January 2025
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA.
View Article and Find Full Text PDFBackground: The full pentavalent (DPT-HepB-Hib) vaccination is the main strategy to prevent five communicable diseases in early childhood, especially in countries with huge communicable disease burdens like Ethiopia. Exploring spatial distributions and determinants of full pentavalent vaccination status in minor ecological areas in Ethiopia is crucial for creating targeted immunization campaigns and monitoring the advancement of accomplishing sustainable development goals. This study aimed to investigate the spatial disparities and determinants of full pentavalent vaccination among 12-23-month-old children in Ethiopia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!